Mundipharma Research GmbH & Co KG
Quick facts
Marketed products
- Laxative · Other
- oxycodone naloxone tablet · Pain Management
Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is an opioid antagonist included to reduce abuse potential by blocking euphoric effects if the tablet is tampered with.
Phase 3 pipeline
- MR308 · Pain Management
MR308 is a selective antagonist of the P2X3 receptor that reduces pain signaling in sensory neurons. - Oxycodone & naloxone combination, prolonged release · Pain management
Oxycodone is a mu-opioid receptor agonist, while naloxone is a mu-opioid receptor antagonist. - Oxycodone/Naloxone Prolonged Release tablets · Pain Management
Oxycodone acts as a mu-opioid receptor agonist to provide analgesia, while naloxone is included to reduce the potential for abuse by blocking opioid effects if the tablet is crushed or dissolved. - oxycodone prolonged release tablet
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Mundipharma Research GmbH & Co KG portfolio CI brief
- Mundipharma Research GmbH & Co KG pipeline updates RSS
Frequently asked questions about Mundipharma Research GmbH & Co KG
What are Mundipharma Research GmbH & Co KG's marketed drugs?
Top marketed products include Laxative, oxycodone naloxone tablet.
What is Mundipharma Research GmbH & Co KG's pipeline?
Mundipharma Research GmbH & Co KG has 4 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include MR308, Oxycodone & naloxone combination, prolonged release, Oxycodone/Naloxone Prolonged Release tablets, oxycodone prolonged release tablet.
Related
- Laxative · Other
- oxycodone naloxone tablet · Pain Management
- Sector hub: All tracked pharma companies